Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Rani Therapeutics Holdings (RANI) Return on Sales (2020 - 2025)

Rani Therapeutics Holdings has reported Return on Sales over the past 6 years, most recently at 5.82% for Q4 2025.

  • Quarterly results put Return on Sales at 5.82% for Q4 2025, up 948.0% from a year ago — trailing twelve months through Dec 2025 was 24.72% (up 3032.0% YoY), and the annual figure for FY2025 was 24.72%, up 3032.0%.
  • Return on Sales for Q4 2025 was 5.82% at Rani Therapeutics Holdings, up from 39.66% in the prior quarter.
  • Over the last five years, Return on Sales for RANI hit a ceiling of 42.37% in Q3 2024 and a floor of 74.06% in Q1 2025.
  • Median Return on Sales over the past 5 years was 5.82% (2025), compared with a mean of 7.01%.
  • Biggest five-year swings in Return on Sales: surged 4521bps in 2023 and later tumbled -9103bps in 2025.
  • Rani Therapeutics Holdings' Return on Sales stood at 19.54% in 2021, then tumbled by -60bps to 31.27% in 2022, then skyrocketed by 135bps to 10.84% in 2023, then crashed by -241bps to 15.29% in 2024, then skyrocketed by 62bps to 5.82% in 2025.
  • The last three reported values for Return on Sales were 5.82% (Q4 2025), 39.66% (Q3 2025), and 43.67% (Q2 2025) per Business Quant data.